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Abstract
Objective: There is an established literature on cannabis expectancies and how these relate to patterns of cannabis 
use and clinical outcomes. However increasingly we are becoming interested in how cannabis expectancies shape the 
subjective experiences people have during drug use, and vice versa. Here we present data reporting how cannabis 
expectancies relate to subjective experiences after cannabis. Additionally we will determine whether an index of 
psychosis proneness (schizotypy) is related to cannabis expectancies. 
Method: A sample of recreational cannabis users (n=137) completed the brief Schizotypal Personality Questionnaire, 
the Cannabis Experiences Questionnaire and the Marijuana Effects Expectancy Questionnaire. 
Results: Cannabis expectancies correlated with the subjective experiences reported in the immediate high from 
cannabis. However, only Cognitive and Behavioural Impairment expectancies were correlated with after effects from 
cannabis. There were no significant correlations between schizotypy and cannabis expectancies. 
Conclusion: Cannabis expectancies are related to the immediate experiences subjectively felt after smoking 
cannabis. Further research is necessary to determine which clinically significant personality traits shape cannabis 
expectancies. 
Keywords: Cannabis expectancies; Schizotypy; Substance use; 
Schizophrenia and cannabis experiences
Introduction
Do expected effects of cannabis relate to the experiences people 
have when using the drug? An individual’s expectancies for a substance 
capture how they expect to be affected during substance use and are 
shaped by information from the environment (e.g., media, peers, 
observing others) as well as subjective experiences with that particular 
substance when use occurs [1,2]. Traditionally, expectancies have 
been considered in alcohol research, and are related to both adult and 
adolescent drinking behaviours [3-5]. More recently expectancies have 
been investigated in relation to cannabis use, with the previous results 
from alcohol research largely being replicated [6-8]. Given the role 
for expectancies to shape patterns of substance use, the investigation 
of cannabis expectancies has relevance not only for substance use 
problems in the general (psychologically healthy) population, but also 
for individuals with serious mental health problems. For instance, 
compared to the general population, rates of cannabis use are 
elevated in patients with schizophrenia [9,10] and psychosis prone 
healthy volunteers from the general population [11]. In those with 
schizophrenia, substance use can lead to variability in treatment and 
symptom outcomes [12]. Therefore determining whether cannabis 
expectancies vary according to vulnerability for a mental illness such 
as schizophrenia could highlight reasons for use, potentially explain 
variations in subjective experiences with a substance and assist in 
the development of effective psychological interventions to target 
substance use in psychologically vulnerable populations [13].
Few studies have investigated cannabis expectancies in patients 
with schizophrenia. Green, Kavanagh and Young [14] reported that 
patients with psychosis had the same expectancies for cannabis and 
used the same quantities on each occasion but with less frequency 
when compared to healthy controls. However, psychosis patients 
displayed more cannabis dependent-like behaviours (e.g., withdrawal 
symptoms) and were more driven to change their consumption than 
healthy controls. Self-reported negative effects of cannabis predicted 
of cannabis use over a four week follow up period in the patients 
with psychosis but not control participants. Despite there being 
no differences between the patients and controls on their overall 
expectancies for cannabis, cannabis expectancies appeared to behave 
in differential manner in the two groups. 
Given that experiences with a substance shape expectations of 
how the drug will affect people on future occasions, it is important to 
consider subjective drug experiences in a systematic manner. Indeed, 
the subjective experiences people have when smoking cannabis have 
been related to both patterns of and reasons for cannabis use [14-16]. 
Aside from the management of psychotic symptoms, patients with 
schizophrenia and healthy controls report using cannabis for the same 
reasons [17]. Subjective experiences after using cannabis may change 
as a psychotic disorder emerges in a young person. Those at risk for 
developing psychosis report feeling more anxious, depressed and 
suspicious after cannabis use [18]. Whilst, in those with recent onset 
psychosis, the first psychotic symptoms occurred after cannabis use 
[18]. Previously it has been reported that psychotic-like experiences 
after cannabis use are related to psychosis proneness or schizotypy in 
the general population [19-22].
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Given that the subjective experiences people report after cannabis 
appear to differ according to schizotypy or psychosis proneness, it is also 
possible that cannabis expectancies will also vary. Particularly since the 
experiences people have with cannabis influence cannabis expectancies 
[23]. Therefore we investigated the relationship between cannabis 
expectancies, self-reported subjective experiences with cannabis and 
schizotypy. Our primary hypothesize is that psychotic-like experiences 
during the cannabis high will be related to, and predictive of, negative 
expectancies and the pleasurable cannabis experiences to positive 
cannabis expectancies. The relationship between cannabis expectancies 
and other cannabis experiences will also be reported for completeness. 
Given that the findings for expectancies differing between patients with 
psychosis and healthy participants are limited we will test a secondary 
hypothesize that negative cannabis expectancies will be positively 
correlated with schizotypy scores. To ensure that our sample is in 
keeping with previous studies we hypothesize that we will replicate 
previous literature: expectancies will be related to patterns of cannabis 
use, more specifically people who had used cannabis at least once 
would score higher on the positive cannabis expectancies.
Method
Participants
An opportunity sample of 137 young adults (24% male; mean age 
22.01 (SD 5.50) years) were recruited through a local university in 
Manchester, UK. Participants did not receive financial compensation 
for completing the study. Other data from these participants has been 
reported in Barkus et al. [20].
Measures
Schizotypy: Participants completed the brief 22-itemed Schizotypal 
Personality Questionnaire (SPQB) [24] comprising the most reliable 
items from the longer Schizotypal Personality Questionnaire [25]. 
The SPQB produces a total score and three sub-scales: ‘Disorganized’ 
(SPQB-D), ‘Cognitive-Perceptual’ (SPQB-CP), ‘Interpersonal’ 
(SPQB-I) and a Total score.
Drug use: Frequency of cannabis use was categorized: Only once 
or twice, At least once a year, At least once a week, and At least once 
a month. We recorded when they smoked cannabis (During the 
morning, during the day, during the evening, frequently during the day 
and night) and other recreational drugs. Time of day when cannabis 
was smoked was recorded as an indicator of the degree of intrusiveness 
of cannabis use.
Experiences with cannabis: The properties of the Cannabis 
Experience Questionnaire (CEQ) have been reported elsewhere [20-
22]. Briefly, participants respond to a list of experiences describing 
immediate (‘high) and after effects associated with cannabis on a 
Likert scale: Never, Occasionally, Sometimes, More often than not, 
and Always. The items formed four subscales, two for the immediate 
effects (Paranoid-Dysphoric and Euphoric) and two for after effects 
(Amotivational and Psychosis after effects) [22]. The CEQ can be 
completed by participants who smoke cannabis at least once in their 
life.
Marijuana effects expectancy questionnaire: The MEEQ [26] 
was designed to record expectations for the effects of cannabis; it 
can be completed regardless of whether an individual has taken 
cannabis. It has six subscales: Cognitive and Behavioural Impairment 
(CBI), Relaxation and Tension Reduction (RTR), Social and Sexual 
Facilitation (SSF), Perceptual Cognitive Enhancement (PCE), Global 
Negative Effects (GNE), and Craving and Physical Effects (CPE).
Procedure
Respondents completed the CEQ, MEEQ and the SPQB as fully and 
honestly as possible in their own time and returned them to a labelled 
post box in a communal area of the university. Respondents were only 
identifiable by a number.  The current data analysis was performed 
using SPSS version 15. The study had ethical approval as part of a larger 
project examining psychosis risk factors in a non-clinical population.
Statistical analysis
All variables approximated to a normal distribution except the SPQB 
subscales which required a logarithmic transformation. In the interests 
of reducing false positive results the significance level to be reached 
was 1%. In general terms, t-tests were used when the independent 
variable had two groups, analysis of variance (ANOVA) was used 
when the independent variable had three or more groups. Scheffe 
post hoc analysis was used if the ANOVAs proved to be significant. 
Chi-square tests were used when associations between categorical 
variables were being tested. The Pearson’s correlations were used to 
explore the relationship between the MEEQ subscales schizotypy and 
cannabis experiences. Untransformed means are presented for ease of 
interpretation. In addition, regression analyses have been performed to 
determine which variables predict cannabis experiences. 
Results
Participants
72.5% of our sample reported having used cannabis at least once. 
There was no association between gender and smoking cannabis or 
polydrug status. Of the total sample, 40.9% had used only cannabis, 
while 33.6% of the total sample were polydrug users (i.e., had used at 
least one other drug besides cannabis). The number of other drugs 
(besides cannabis) used by participants varied between 1 (41% of the 
polydrug users) and 10 (0.7%). Other recreational drugs of choice 
(listed according to frequency of reporting) included cocaine (19%), 
ecstasy (19%), LSD (13%), amphetamine (11%), magic mushrooms 
(7%), poppers (7%) and ketamine (4%). Drugs used by fewer than 2% 
of participants included: solvents, GHB, nutmeg, benzodiazepines, 
MDA, opiates and barbiturates. Three participants who had not 
smoked cannabis but had used other drugs (LSD, cocaine or morphine) 
were included in the analyses reported below as non-cannabis users.
There were no gender differences on MEEQ subscales, nor any 
associations between gender and patterns of cannabis or other drug 
use. There were no significant differences on the MEEQ subscales for 
the frequency of cannabis use. In keeping with the previous literature 
males had higher scores on the disorganised dimension from the SPQB 
(Male: 2.64 (SD=1.85), Female=1.56 (SD=1.65); t=3.41, df=46.62, 
p=0.002). There were no differences for cannabis use status, polydrug 
use status or frequency of use on the schizotypy scores. 
MEEQ and SPQB
There were no significant correlations between the subscales 
from the MEEQ and the SPQB subscales. Given that there were no 
significant correlations between MEEQ and SPQB, regression models 
using MEEQ subscales to predict schizotypy were not persuade further. 
MEEQ and cannabis use
There were significant differences between cannabis users and 
non-users on two of the MEEQ subscales. For the SSF subscale (t=3.99, 
df=58.33, p<0.001) those who had not smoked cannabis scored 
significantly higher (mean=5.41, SD=2.26) than those who had smoked 
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cannabis (mean=3.80, SD=1.80). For the GNE subscale (t=5.55, df=135, 
p<0.001) those who had not smoked cannabis had higher negative 
evaluations (mean=4.72, SD=2.24)) compared to those who had used 
cannabis (mean=2.39, SD=2.21) (Table 1).
Participants were divided into three groups according to whether 
they had used no drug (n=35), cannabis only (n=56) or had used 
one other drug besides cannabis (polydrug use; n=46). There were 
significant differences on four MEEQ subscales (Table 1). Both the no 
drug group and the polydrug group (at a trend level) scored higher than 
the cannabis only group on the CBI subscale. The no drug group scored 
significantly higher on the SSF compared to the cannabis only and the 
polydrug groups. For the GNE subscale the no drug group scored 
significantly higher than both the cannabis only and the polydrug 
groups. For the RTR subscale the no drug group had significantly 
higher scores than the polydrug group.
MEEQ and CEQ subscales
The correlations between the MEEQ subscales and the CEQ 
subscales are presented in Table 2. Both the SSF and the GNE 
subscales did not correlate significantly with any CEQ subscales. There 
were significant correlations between the MEEQ and the immediate 
response to cannabis subscales, only the CBI subscale from the MEEQ 
was correlated with the after effect subscales from the CEQ. 
In order to determine which MEEQ subscales provided unique 
variance in predicting cannabis experiences, a series of regression 
models using Enter method were performed. The results of these 
will now be described. When considering the immediate Psychosis-
Dysphoric experiences from cannabis (R2=0.284, adjusted R2=0.237; 
F(6,92) =6.08, p<0.001), high Cognitive and Behavioural Impairment, 
low Relaxation and Tension Reduction, and high Perceptual Cognitive 
Enhancement scores predicted these immediate experiences from 
cannabis (Table 3). 
The results for the immediate Euphoric experiences (R2=0.380, 
adjusted R2=0.339; F(6,92) =9.39, p<0.001) are displayed in Table 4. 
Low Cognitive and Behavioural Impairment, high Perceptual Cognitive 
Enhancement and high Craving and Physical Effects were predictive 
of high endorsement of Euphoric Experiences in the immediate high 
from cannabis.
Table 5 displays the results for the regression model predicting 
Amotivational after effects from cannabis (R2=0.290, adjusted 
R2=0.244; F(6,92) =6.26, p<0.001). High scores on Cognitive and 
Behavioural Impairment, Perceptual Cognitive Enhancement, and low 
scores on Relaxation and Tension Reduction predicted high scores on 
for Amotivational after effects. 
Finally, the MEEQ subscales which predicted Psychosis-like after 
effects were also considered (R2=0.213, adjusted R2=0.161; F(6,92) 
=4.14, p=0.001). High scores on Cognitive and Behavioural Impairment 
and low scores on Relaxation and Tension Reduction were significant 
of the Psychosis-like after effects (Table 6). 
Discussion
The study examined the relationship between cannabis expectancies, 
subjective cannabis experiences and schizotypy. Those who had 
not used cannabis had higher scores on the Global Negative Effects 
subscale and Social and Sexual Facilitation subscales from the MEEQ. 
Drug use
F value, df=2,134, p value Scheffe values (p value)
No drugs (n=35) Cannabis Only (n=56) Polydrug use (n=46)
CBI 6.89 (1.75) 5.48 (2.47) 6.57 (2.32) F=5.06, p=0.008 No drugs V cannabis only (0.017)Cannabis only V Polydrugs (trend 0.058)
SSF 5.46 (2.21) 4.16 (1.96) 3.46 (1.66) F=10.74, p<0.001 No drugs V cannabis only (0.009)No drugs V Polydrugs (<0.001)





(2.12) F=4.12, p=0.01 No drugs V Polydrugs (0.012)
Key: CBI: Cognitive and Behavioural Impairment; RTR: Relaxation and Tension Reduction; SSF: Social and Sexual Facilitation; PCE: Perceptual Cognitive Enhancement; 
GNE: Global Negative Effects; CPE: Craving and Physical Effects (CPE).
Table 1: The effects of polydrug use status on MEEQ subscales.
Paranoid Dysphoric Euphoric Amotivational After Effects Psychosis-like After Effects
CBI 0.434 (p<0.001) ns 0.463 (p<0.001) 0.395 (p<0.001)
RTR ns 0.349 (p<0.001) Ns ns
PCE 0.232 (0.021) 0.473 (p<0.001) Ns ns
CPE 0.200 (0.047) 0.233 (0.020) Ns ns
Key: n=99 (cannabis users only). CBI: Cognitive and Behavioural Impairment; RTR: Relaxation and Tension Reduction; SSF: Social and Sexual Facilitation; PCE: 
Perceptual Cognitive Enhancement; GNE: Global Negative Effects; CPE: Craving and Physical Effects (CPE).
Table 2: The correlations between the MEEQ and the CEQ subscales.
Unstandardized Coefficients Standardized Coefficients
MEEQ Subscale B Std. Error Beta t Sig.
Cognitive and Behavioural Impairment 1.882 .538 .360 3.500 0.001
Relaxation and Tension Reduction -1.924 0.739 -0.309 -2.604 0.011
Social and Sexual Facilitation -.217 0.822 -0.030 -0.264 0.793
Perceptual Cognitive Enhancement 1.924 0.710 0.296 2.709 0.008
Global Negative Effects -0.357 0.646 -0.061 -0.553 0.582
Craving and Physical Effects 0.774 0.778 0.096 0.995 0.322
Table 3: The Enter Regression model results for Psychosis-Dysphoric immediate cannabis experiences.
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This suggests users minimise the general negative effects of cannabis, 
while non-users perceive cannabis to be more socially facilitating than 
users. Consequently, user’s expectations about cannabis are not simply 
more positive than non-users as hypothesized, rather it appears cost-
benefit reasoning exists potentially with anticipated positive effects 
not living up to expectations but negative expectancies about cannabis 
also not being realised after use. This is supported by previous research 
reporting that those who had not smoked cannabis have higher global 
negative expectations [6-8,14]. Many of the reason given by patients 
for cannabis use are centred on social situations [17], although in the 
current sample non-users had higher expectations for cannabis to be 
relaxing, socially and sexually facilitating. This suggests the perceived 
reasons for use in patients may not directly align with drug expectancies 
in users, particularly given that there were no significant correlations 
between schizotypy scores and cannabis expectancies. 
When considering the degree of exposure to recreational drugs, 
the Global Negative Effects subscale and Social and Sexual Facilitation 
subscales were also sensitive to group differences. There was a linear 
effect for Social and Sexual Facilitation, Global Negative Effects and 
Relaxation and Tension Reduction subscales from the MEEQ with the 
no drug exposure group scoring highest, cannabis only an intermediary 
group and the polydrug group scoring the lowest. Polydrug users and 
those with no exposure to recreational drugs had higher ratings for 
the Cognitive Behavioural Impairment from cannabis. These results 
suggest polydrug users are more likely to minimise general negative 
effects of cannabis, but also do not perceive the relaxing benefits 
stereotypically associated with cannabis. However, we did not explicitly 
ask participants whether they used cannabis in combination with other 
recreational drugs so cannot conclude whether these scores reflect a 
general attitude to drugs or the effects of using other drugs contiguous 
with cannabis. 
There was partial support for the hypothesis that psychotic-like 
experiences after cannabis use will be related to negative expectancies, 
and pleasurable cannabis experiences will be related to positive 
cannabis expectancies. Only the Cognitive and Behavioural Impairment 
subscale from the MEEQ was associated with both the immediate 
and after effects from cannabis, perhaps reflecting a recognition that 
the cognitive effects of cannabis persist after the initial high from 
cannabis has abated. The two immediate cannabis effects subscales 
from the CEQ were correlated with nearly all of the MEEQ subscales. 
In the regression models the Cognitive and behavioural Impairment 
subscale were predictive of all the cannabis experiences; Perceptual 
Cognitive Enhancement scores were predictive of the immediate 
cannabis experiences and the Amotivational after-effects. Lower scores 
on Relaxation and Tension Reduction were predictive of the more 
negative experiences from cannabis in both the immediate high and 
the after effects; this would suggest that those who have expectancies 
of enjoying cannabis are less likely to experience deleterious subjective 
effects. Conversely high Craving and Physical Effects expectancies 
were predictive of Euphoric immediate effects; perhaps pointing 
to immediate enjoyment of the high being a motivation for future 
use. The reasons for cannabis use are primarily focused upon the 
immediate effects of cannabis [17]. Peters et al. [18] reported that 
their patient groups (clinical high risk for and recent onset patients 
with psychosis) reported longer lasting subjective after effects from 
cannabis than healthy controls. Perhaps individuals, who are sensitive 
to the immediate high from cannabis, experience more after effects 
as well. Sensitivity to the effects of the immediate high from cannabis 
could strongly reinforce cannabis expectancies and shape expectations 
for future effects when smoking cannabis. An alternative explanation 
for cannabis expectancies being correlated with the immediate rather 
than after effects from cannabis, may be found in focus that the media 
Unstandardized Coefficients Standardized Coefficients
MEEQ Subscale B Std. Error Beta t Sig.
Cognitive and Behavioural Impairment -0.912 0.337 -0.259 -2.705 0.008
Relaxation and Tension Reduction 0.177 0.463 0.042 0.383 0.703
Social and Sexual Facilitation 0.153 0.516 0.032 0.297 0.767
Perceptual Cognitive Enhancement 2.386 0.445 0.545 5.358 0.000
Global Negative Effects -0.731 0.405 -0.184 -1.804 0.074
Craving and Physical Effects 1.429 0.488 0.264 2.928 0.004
Table 4: The Enter Regression model results for Euphoric immediate cannabis experiences.
Unstandardized Coefficients Standardized Coefficients
MEEQ Subscale B Std. Error Beta t Sig.
Cognitive and Behavioural Impairment 1.235 0.279 0.454 4.430 0.000
Relaxation and Tension Reduction -0.908 0.383 -0.280 -2.369 0.020
Social and Sexual Facilitation -0.202 0.427 -0.054 -0.473 0.637
Perceptual Cognitive Enhancement 0.797 0.368 0.235 2.163 0.033
Global Negative Effects -0.419 0.335 -0.137 -1.251 0.214
Craving and Physical Effects 0.180 0.404 0.043 0.445 0.657
Table 5: The Enter Regression model results for Amotivational after Effects from cannabis.
Unstandardized Coefficients Standardized Coefficients
MEEQ Subscale B Std. Error Beta t Sig.
Cognitive and Behavioural Impairment 0.494 0.136 0.392 3.634 0.000
Relaxation and Tension Reduction -0.369 0.187 -0.246 -1.972 0.052
Social and Sexual Facilitation -0.037 0.208 -0.021 -0.176 0.861
Perceptual Cognitive Enhancement 0.308 0.180 0.196 1.711 0.090
Global Negative Effects -0.082 0.163 -0.058 -0.503 0.616
Craving and Physical Effects -0.091 0.197 -0.047 -0.463 0.645
Table 6: The Enter Regression model results for Psychosis-like After Effects from cannabis.
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places on the immediate high from cannabis, paying little attention to 
the potential for longer lasting after effects. Learning environment and 
exposure to media messages will shape cannabis expectancies, which 
in turn may shape experiences, which will reciprocate to potentially 
modify expectancies over time with repeated exposure to the drug. 
Schizotypy scores were not related to expectancies. This suggests 
that those who score high or low on schizotypy have the same 
expectations about the effects of cannabis. Perhaps lending support 
for individual differences in cannabis experiences being underpinned 
by biological (genes, dopamine regulation) rather than social factors 
(openness to unusual experiences). Additionally it may offer tentative 
evidence against those with higher schizotypy scores using cannabis 
to self-medicate. In support of these findings, previously Hides et al. 
[27] reported that cannabis expectancies were not related to psychotic 
symptoms in patients. However, some studies report patients with 
psychosis use cannabis to enhance mood [17,28]. This could be an 
indirect effect on symptoms and assist in facilitating social interactions. 
It would be possible to examine this mediating effect in healthy 
individuals with high schizotypy scores.
The current study only used a brief schizotypy measure and it 
may be that the items which are sensitive to cannabis expectancies 
were not included. There may be other aspects of personality which 
are more closely related to cannabis expectancies and use such as 
impulsivity (see data on the acquired preparedness model) [29] than 
schizotypy. Alternatively the effect of schizotypy may be too small to 
detect in the relatively small sample size reported here. Furthermore 
we used a relatively high functioning sample that only used cannabis 
recreationally. Collecting data from a different sample could produce 
alternative results. In the general population it may be possible to 
recruit individuals who use cannabis heavily, perhaps resulting in 
associations between schizotypy and expectancies.
In conclusion we found similar findings to previous research for the 
effects of patterns of use on cannabis expectancies. Schizotypy scores 
and cannabis expectancies were not related. Immediate effects from 
cannabis were correlated with a greater number of cannabis expectancy 
subscales than the cannabis after effects. Replication of the current data 
is required in a larger sample and with a more detailed schizotypy scale. 
Furthermore other personality traits need to be investigated which may 
be related to both cannabis experiences and expectancies. Additionally 
with a larger sample other analysis techniques such as mediation 
and structural equation modelling would be beneficial to address 
the direction of the relationship between cannabis expectancies, 
experiences and possible role schizotypy may play.
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